That was the topic of a new report from Bloomberg which reported that vaccine makers, pharmacy chains, makers of at-home rapid tests - and generally anyone who was cashing checks off the back of the Covid-19 hysteria - is now seeing business suffer, or going belly up. 

The report notes that the biggest "loser" from the nation's return to common sense is Pfizer, who was a major beneficiary of the pandemic surge. The company just dramatically reduced its annual sales outlook by $9 billion on Monday. This comes amid waning demand for its Covid vaccines and Paxlovid therapy.

Moderna also warned this week that "it's too early to accurately project where vaccination rates will land" for the upcoming year. Shares are the lowest they've been since November 2020, the report says. 

Pfizer shares are down 35% this year and Modena shares are down 49% as the public's appetite for mRNA technology has taken a back seat to new "miracle" weight loss drugs like Ozempic, which have become the key headline on Wall Street healthcare desks over the last several months.